PCSK9 and Other metabolic disease: CU262 stands out by significantly influencing the cholesterol metabolic axis (mevalonate pathway and PCSK9)—a feature that is not widely documented for many probiotics—suggesting that strains may have strain-specific “signatures” in their mechanism, an important consideration for probiotic selection in metabolic disease intervention [101].